Definium Therapeutics announced a proposed $500 million public offering of common shares and pre-funded warrants on June 22, 2026.
The biopharmaceutical company granted underwriters a 30-day option to buy up to $75 million in additional shares.
Completion of the underwritten offering depends on market conditions and final terms.
Definium has not yet disclosed the intended use of the capital raise proceeds.
The announcement follows a period of significant stock price appreciation for the company.